# Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

> **NCT02511639** · PHASE3 · COMPLETED · sponsor: **Istituto Oncologico Veneto IRCCS** · enrollment: 110 (actual)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Aromatase Inhibitors

## Key facts

- **NCT ID:** NCT02511639
- **Lead sponsor:** Istituto Oncologico Veneto IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-30
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-07-31
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2020-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02511639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02511639, "Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT02511639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*